- Home
- NRSN vs ICU Comparison
NRSN vs ICU Comparison
Compare NRSN & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRSN | ICU |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2M | 13.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NRSN | ICU |
|---|---|---|
| Price | $0.51 | $2.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 238.8K | 64.1K |
| Earning Date | 03-31-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,234,000.00 |
| Revenue This Year | N/A | $53.00 |
| Revenue Next Year | $583.67 | $50.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 814.07 |
| 52 Week Low | $0.25 | $0.22 |
| 52 Week High | $1.30 | $5.38 |
Technical Indicators
Market Signals| Indicator | NRSN | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 42.47 | 34.92 |
| Support Level | $0.39 | $2.21 |
| Resistance Level | $0.74 | $3.50 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 67.23 | 4.69 |
Price Performance
Historical ComparisonAbout NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.